Bardoxolone: A Comprehensive Monograph on a Promising Nrf2 Activator from Bench to Clinical Disappointment

1.0 Executive Summary

Bardoxolone is a first-in-class, semi-synthetic oleanane triterpenoid and a potent activator of the Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. Initially developed for its antineoplastic potential, the compound's trajectory was dramatically altered by the serendipitous discovery of its ability to significantly increase the estimated Glomerular Filtration Rate (eGFR) in early-phase oncology trials. This observation prompted a strategic pivot to nephrology, positioning Bardoxolone Methyl—the clinically developed methyl ester form—as a potential breakthrough therapy for chronic kidney disease (CKD), a condition with a profound unmet medical need.

The initial promise of Bardoxolone Methyl was bolstered by the Phase 2 BEAM study, which demonstrated substantial and sustained increases in eGFR in patients with diabetic kidney disease (DKD). This success, however, was overshadowed by concerning signals, including a paradoxical increase in albuminuria. The subsequent large-scale, pivotal Phase 3 BEACON trial was terminated prematurely due to an unacceptable and statistically significant increase in heart failure-related hospitalizations and deaths in the treatment arm. Post-hoc analyses revealed that this severe adverse event was likely driven by acute fluid and sodium retention, particularly in patients with pre-existing cardiovascular risk factors.

Despite this major setback, development continued with a refined strategy focusing on rare kidney diseases with inflammatory components, such as Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD). This new phase of investigation was supported by meticulously designed trials like CARDINAL and FALCON, which incorporated stringent exclusion criteria to mitigate the known cardiovascular risks. While these studies again demonstrated a consistent ability to increase on-treatment eGFR, they failed to provide convincing evidence of a durable, disease-modifying effect on the progression of kidney disease. The observed eGFR benefit was largely reversible upon drug withdrawal, and crucially, later studies like the Japanese AYAME trial showed no reduction in the hard clinical endpoint of progression to end-stage kidney disease (ESKD).

This persistent disconnect between the improvement of a surrogate renal biomarker (eGFR) and the lack of benefit on patient-relevant hard outcomes, coupled with the underlying safety concerns, ultimately led to the rejection of Bardoxolone Methyl by global regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In May 2023, following the disappointing results of the AYAME trial, the sponsors announced the discontinuation of all clinical development for Bardoxolone in CKD. Bardoxolone's journey serves as a critical and cautionary case study in drug development, highlighting the limitations of surrogate endpoints, the intricate and often inseparable link between renal and cardiovascular physiology, and the paramount importance of demonstrating a favorable benefit-risk profile on hard clinical outcomes.

2.0 Introduction to Bardoxolone

Bardoxolone is a synthetic triterpenoid compound derived from the naturally occurring oleanolic acid, a molecule found in numerous plants.[1] Through extensive medicinal chemistry efforts, the weak biological activity of the parent scaffold was substantially enhanced, leading to the creation of Bardoxolone and its clinically developed form, Bardoxolone Methyl (RTA 402).[1] The development of Bardoxolone was predicated on targeting a fundamental biological pathway: the Kelch-like ECH-associated protein 1 (Keap1)-Nrf2 signaling axis. The Nrf2 pathway is a master regulator of cellular defense against oxidative stress and inflammation, making it a highly attractive therapeutic target for a wide range of chronic diseases characterized by these pathological processes.[1]

Initially, Bardoxolone was investigated for its potential antineoplastic and anti-inflammatory activities.[7] Its ability to induce apoptosis in cancer cells under high oxidative stress made it a candidate for oncology indications.[8] However, during a first-in-human Phase 1 trial in patients with advanced cancers, a consistent and unexpected pharmacological effect was observed: a significant increase in the estimated Glomerular Filtration Rate (eGFR), a key measure of kidney function.[4] This serendipitous finding prompted a complete strategic repositioning of the drug development program. The focus shifted from oncology to nephrology, specifically targeting chronic kidney disease (CKD), a progressive and debilitating condition with limited therapeutic options and a high unmet medical need.[12]

This pivot set the stage for a complex and ultimately tumultuous clinical development journey. The central narrative of Bardoxolone became a compelling conflict between its potent, mechanistically plausible, and biomarker-supported effects on renal function and the emergence of severe, mechanism-linked safety liabilities. The drug's ability to consistently raise eGFR across diverse patient populations fueled immense hope, but its association with adverse cardiovascular events, particularly heart failure, created an insurmountable hurdle. The story of Bardoxolone is therefore not merely one of a failed drug, but a profound lesson in the complexities of targeting fundamental biological pathways and the critical importance of understanding the relationship between surrogate endpoints and true, patient-centric clinical outcomes.

3.0 Molecular Profile and Physicochemical Properties

3.1 Chemical Identity and Structure

Bardoxolone is a complex small molecule belonging to the triterpenoid class. For clarity in scientific and regulatory discourse, it is essential to distinguish between the parent carboxylic acid form (Bardoxolone) and its methyl ester prodrug (Bardoxolone Methyl), which was the form predominantly used in clinical trials to enhance its pharmacokinetic properties.[14]

The systematic International Union of Pure and Applied Chemistry (IUPAC) name for Bardoxolone is (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylic acid.[8] The IUPAC name for Bardoxolone Methyl is (+)-methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate.[7]

The molecular formula for Bardoxolone is $C_{31}H_{41}NO_{4}$, with a corresponding molecular weight of approximately 491.7 g/mol.[8] Bardoxolone Methyl has the molecular formula $C_{32}H_{43}NO_{4}$ and a molecular weight of approximately 505.7 g/mol.[11]

For unambiguous identification in chemical databases and literature, the following structural identifiers are used:

• CAS Number: The Chemical Abstracts Service (CAS) registry number for Bardoxolone is 218600-44-3.[8] The CAS number for Bardoxolone Methyl is 218600-53-4.[11]
• DrugBank ID: Bardoxolone is registered under DrugBank ID DB12651.[8] Its methyl ester, Bardoxolone Methyl, is associated with DB05983, though some databases cross-reference these identifiers.[21]
• InChI/InChIKey/SMILES: These machine-readable formats provide a complete and standardized chemical description of the molecules.
• Bardoxolone InChIKey: TXGZJQLMVSIZEI-UQMAOPSPSA-N.[8]
• Bardoxolone Methyl InChIKey: WPTTVJLTNAWYAO-KPOXMGGZSA-N.11 The full InChI and SMILES strings for both molecules are available in public chemical databases.8

3.2 Synonyms and Formulations

Throughout its development, Bardoxolone and its methyl ester have been referred to by various synonyms and code names. Bardoxolone (the acid form) is commonly known as CDDO or RTA 401.[8] Bardoxolone Methyl is widely referred to as CDDO-Me, CDDO-methyl ester, or by its development code name, RTA 402.[3] Understanding these synonyms is critical for navigating the extensive body of preclinical and clinical literature.

The formulation of Bardoxolone Methyl evolved significantly during its clinical development. Early trials utilized a micronized crystalline preparation of the drug substance, supplied in gelatin capsules.[10] However, due to challenges with oral bioavailability, an improved formulation was developed. This advanced formulation was an amorphous spray-dried dispersion (SDD), which was designed to enhance the dissolution rate and subsequent absorption of the poorly soluble compound. The SDD formulation was used in later pivotal trials, including the BEACON study, and demonstrated higher systemic bioavailability compared to the crystalline form.[15] This transition from a simple crystalline form to a more complex SDD formulation underscores a key pharmaceutical development effort aimed at optimizing drug exposure and overcoming the inherent physicochemical limitations of the molecule.

3.3 Physicochemical Characteristics and Druglikeness Profile

An analysis of Bardoxolone's physicochemical properties provides critical context for its observed pharmacokinetic behavior. Computed descriptors indicate that the molecule has 5 hydrogen bond acceptors and 1 hydrogen bond donor, with only 1 rotatable bond, reflecting its rigid, polycyclic structure.[8] Its topological polar surface area (TPSA) is calculated to be 95.23 $Å^2$.[8]

A key characteristic of Bardoxolone is its high lipophilicity, with a calculated partition coefficient (XLogP) value between 6.3 and 6.4.[8] This property places the molecule in violation of one of Lipinski's Rule-of-Five criteria for "druglikeness" (specifically, LogP > 5).[25] This high lipophilicity, while potentially favorable for cell membrane permeability, is a strong indicator of poor aqueous solubility. This fundamental physicochemical property directly predicts significant challenges in pharmaceutical development. Poor solubility often leads to dissolution rate-limited absorption from the gastrointestinal tract, which can result in low and highly variable oral bioavailability. This prediction is directly borne out by the clinical pharmacokinetic data, which describe Bardoxolone Methyl's absorption as "slow and saturable" and "less than dose-proportional".[3] The explicit need to develop the advanced SDD formulation to improve bioavailability further confirms that the molecule's inherent physicochemical properties created a major pharmaceutical hurdle.[15] This "un-druglike" lipophilicity was a foundational challenge in its development, influencing dosing strategies and contributing to the high inter-patient pharmacokinetic variability observed in clinical trials.[3]

Property	Bardoxolone	Bardoxolone Methyl	Source(s)
IUPAC Name	(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylic acid	(+)-methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate	7
Synonyms / Code Names	CDDO, RTA 401	CDDO-Me, RTA 402	7
CAS Number	218600-44-3	218600-53-4	8
DrugBank ID	DB12651	DB05983	8
Molecular Formula	$C_{31}H_{41}NO_{4}$	$C_{32}H_{43}NO_{4}$	11
Molecular Weight	491.67 g/mol	505.70 g/mol	11
XLogP	6.3 - 6.4	N/A	8
Topological Polar Surface Area	95.23 $Å^2$	N/A	8
H-Bond Donors	1	N/A	8
H-Bond Acceptors	5	N/A	8
Lipinski's Rule Violations	1 (XLogP > 5)	N/A	25

4.0 Preclinical and Clinical Pharmacology

4.1 Primary Mechanism of Action: Potent Activation of the Nrf2-Keap1 Axis

The primary pharmacological activity of Bardoxolone is the potent activation of the Nrf2 pathway, a critical cellular system for regulating antioxidant and anti-inflammatory responses.[1] Under homeostatic conditions, the transcription factor Nrf2 is sequestered in the cytoplasm by its primary repressor, Keap1. Keap1 acts as an adaptor protein for a Cullin 3-based E3 ubiquitin ligase complex, which continuously targets Nrf2 for ubiquitination and subsequent proteasomal degradation, thereby keeping the pathway's activity low.[5]

Bardoxolone functions as a powerful electrophile, a property conferred by the two α,β-unsaturated carbonyl groups (Michael acceptors) located in its A and C rings.[1] These reactive moieties enable Bardoxolone to form reversible, covalent adducts with specific, redox-sensitive cysteine residues on the Keap1 protein, including Cys-151, Cys-257, Cys-273, and Cys-288.[1] This chemical modification induces a conformational change in Keap1, disrupting its ability to function as an E3 ligase adaptor for Nrf2.[14]

The inhibition of Keap1-mediated degradation leads to the stabilization of newly synthesized Nrf2. This allows Nrf2 to accumulate and translocate from the cytoplasm into the nucleus.[3] Once in the nucleus, Nrf2 heterodimerizes with small Maf proteins and binds to specific DNA sequences known as Antioxidant Response Elements (AREs) or Electrophile Responsive Elements (EpREs) located in the promoter regions of hundreds of cytoprotective genes.[6] This binding initiates the transcription of a coordinated battery of genes encoding for detoxification enzymes (e.g., NAD(P)H:quinone oxidoreductase 1, or NQO1), antioxidant proteins (e.g., heme oxygenase-1), and other stress response mediators.[10] Bardoxolone Methyl has been described as one of the most potent inducers of the Nrf2 pathway to have entered clinical development, providing a strong mechanistic basis for its therapeutic potential in diseases driven by oxidative stress and inflammation.[16]

4.2 Secondary Pharmacological Activities: Inhibition of NF-κB and Pro-inflammatory Mediators

In addition to its primary role as an Nrf2 activator, Bardoxolone exerts significant direct anti-inflammatory effects by inhibiting the Nuclear Factor-kappa B (NF-κB) signaling pathway.[3] NF-κB is a master transcription factor that drives the expression of numerous pro-inflammatory cytokines, chemokines, and adhesion molecules. Bardoxolone's inhibitory action is mediated, at least in part, through the direct covalent modification of a critical cysteine residue (Cys-179) located within the activation loop of IκB kinase β (IKKβ).[3] IKKβ is the key kinase responsible for phosphorylating the inhibitor of κB (IκB), which triggers IκB's degradation and the subsequent release and nuclear translocation of NF-κB. By binding to IKKβ, Bardoxolone prevents this activation step, effectively trapping NF-κB in an inactive complex with IκB in the cytoplasm and suppressing its downstream pro-inflammatory signaling cascade.[3]

This direct inhibition of a major pro-inflammatory pathway is complemented by potent suppression of key inflammatory enzymes. Preclinical studies have demonstrated that Bardoxolone and its methyl ester are highly effective inhibitors of the de novo synthesis of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in activated macrophages, with a reported half-maximal inhibitory concentration ($IC_{50}$) as low as 0.4 nM.[7] Furthermore, the agent has been shown to block the interleukin-1 (IL-1)-induced expression of matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-13 (MMP-13), enzymes involved in tissue degradation during inflammatory processes.[7]

The combination of potent Nrf2 activation and direct NF-κB inhibition creates a powerful, dual-action pharmacological profile. This is not simply an "on" switch for a single protective pathway but rather a comprehensive "rebalancing" of the cellular environment, actively suppressing pro-inflammatory signals while simultaneously bolstering the cell's intrinsic antioxidant and cytoprotective defenses. This synergistic mechanism provides a strong rationale for its broad preclinical efficacy in diverse models of cancer, inflammation, and fibrosis.[12] However, this potent activity is highly concentration-dependent. At low nanomolar concentrations, Bardoxolone Methyl is cytoprotective, primarily by reducing reactive oxygen species (ROS). In stark contrast, at low micromolar concentrations, its effects reverse, and it becomes pro-apoptotic by increasing ROS and depleting intracellular glutathione levels.[2] This dose-dependent duality explains its parallel investigation in two seemingly opposite therapeutic areas: protecting normal tissues in chronic diseases like CKD and inducing cell death in malignant tissues in oncology. This narrow therapeutic window, where the drug can switch from an antioxidant to a pro-oxidant, foreshadowed the potential for off-target toxicities if dosing and drug exposure were not precisely controlled, a concern that would later be realized in clinical trials.

4.3 Pharmacokinetics (PK): Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of Bardoxolone Methyl in humans is characterized by slow absorption, a long elimination half-life, non-linear kinetics at higher doses, and significant inter-subject variability.

• Absorption: Following oral administration, Bardoxolone Methyl is absorbed slowly and exhibits a saturable absorption process. In a Phase 1 study, the median time to reach maximum plasma concentration ($T_{max}$) was approximately 4.1 hours at a 900 mg dose.[3] Pharmacokinetic analyses have consistently shown that increases in drug exposure (as measured by $C_{max}$ and AUC) are less than dose-proportional, particularly at doses exceeding 20 mg of the SDD formulation.[26] This suggests that either the dissolution of the drug in the gastrointestinal tract or the absorption process itself becomes saturated at higher doses.[15] A food-effect study demonstrated that administration with food did not significantly alter the total systemic exposure (AUC) of a 20 mg dose, although it may influence the rate of absorption.[26]
• Distribution and Half-Life: The compound has a relatively long terminal elimination half-life ($t_{1/2}$), which was reported to be approximately 39 hours at the 900 mg/day dose in the Phase 1 oncology trial.[3] This long half-life is a key property that supports a convenient once-daily dosing regimen.[15]
• Variability: A notable and challenging feature of Bardoxolone Methyl's pharmacokinetics is the high degree of inter-patient variability. The coefficient of variation for key PK parameters ranged from 64–77% after the first dose and 39–54% after the final dose at the 900 mg/day level.[3] This high variability can make it difficult to achieve predictable and consistent drug exposure across a patient population, which has implications for both efficacy and safety.
• Metabolism: The publicly available research material lacks detailed information regarding the specific metabolic pathways of Bardoxolone Methyl, such as the cytochrome P450 enzymes involved or the identity of major metabolites. However, this was an area of significant regulatory concern. During its review of the marketing application for Alport syndrome, the European Medicines Agency (EMA) noted that it was unclear from the provided data how Bardoxolone is broken down in the body and whether the end products could impact patient health, suggesting this was an unresolved issue in the drug's characterization.[30]

4.4 Pharmacodynamics (PD): Biomarker and Physiological Responses

The pharmacodynamic effects of Bardoxolone Methyl have been well-characterized in clinical trials, demonstrating clear target engagement and producing a consistent pattern of physiological responses, some of which were therapeutically promising while others were deeply concerning.

• Nrf2 Pathway Activation: Clinical studies successfully confirmed that Bardoxolone Methyl engages its primary molecular target in humans. In the Phase 1 oncology trial, oral administration led to a dose-dependent increase in the mRNA levels of NQO1 in peripheral blood mononuclear cells (PBMCs).[10] As NQO1 is a canonical downstream target gene of Nrf2, this finding served as a crucial pharmacodynamic biomarker, providing direct evidence of Nrf2 pathway activation.[10]
• Renal Effects (eGFR): The most striking and clinically significant pharmacodynamic effect of Bardoxolone Methyl was its ability to induce a rapid, substantial, and sustained increase in eGFR. This effect was observed consistently across a wide range of clinical trials and patient populations, including those with cancer, diabetic kidney disease, Alport syndrome, and other rare forms of CKD.[4] The increase in eGFR typically became apparent within the first four weeks of treatment and was maintained for the duration of therapy.[32]
• Hepatic Effects: A consistent and dose-related pharmacodynamic effect was the elevation of serum liver aminotransferases, specifically alanine aminotransferase (ALT) and aspartate aminotransferase (AST).[10] While such elevations are often a signal of hepatotoxicity, extensive post-hoc analyses of clinical data, along with preclinical experiments, suggested that these increases may be related to the drug's pharmacological activity. It has been proposed that Bardoxolone Methyl induces the transcription and expression of ALT and AST isoforms via Nrf2 activation, rather than causing direct hepatocellular injury. Nevertheless, these liver enzyme elevations remained a prominent safety and tolerability concern throughout the clinical program.[34]
• Metabolic Effects: Treatment with Bardoxolone Methyl was consistently associated with significant and dose-dependent weight loss, an effect that was most pronounced in overweight and obese individuals.[33] Studies suggest this weight loss is primarily attributable to a reduction in fat mass rather than lean muscle mass.[33] However, this was often accompanied by a high incidence of muscle spasms, which raised questions about potential effects on muscle tissue.[31]
• Albuminuria: In a paradoxical and concerning finding, the marked increase in eGFR was frequently accompanied by a concurrent increase in urinary albumin excretion, as measured by the albumin-to-creatinine ratio (ACR).[32] Since increased albuminuria is a well-established marker of glomerular damage and a strong predictor of CKD progression, this finding was a major red flag. It fueled the hypothesis that the eGFR increase was not a sign of renal improvement but rather a consequence of a potentially deleterious hemodynamic effect, such as increased intraglomerular pressure or hyperfiltration.[32]

5.0 Clinical Development and Efficacy Evaluation

The clinical development of Bardoxolone Methyl was a long and complex journey, marked by a dramatic strategic pivot, initial promising results, a pivotal trial failure, and subsequent attempts to find a niche in rare diseases. This history provides a compelling narrative of the challenges inherent in drug development, particularly in the field of nephrology.

Trial Name (Acronym)	NCT ID	Phase	Indication(s)	Key Population	N	Primary Endpoint(s)	Key Outcome & Status
Phase 1 Oncology	N/A	1	Advanced Solid Tumors, Lymphoma	Treatment-refractory cancer patients	47	MTD, DLTs, PK/PD	MTD established at 900 mg/d. Serendipitous eGFR increase observed. Completed.
BEAM	NCT00811889	2b	Diabetic Kidney Disease (DKD)	T2DM, CKD Stage 3b-4 (eGFR 20-45)	227	Change in eGFR at 24 weeks	Met primary endpoint; significant eGFR increase. Completed.
BEACON	NCT01351675	3	Diabetic Kidney Disease (DKD)	T2DM, CKD Stage 4 (eGFR 15-30)	2185	Time to ESKD or CV death	Terminated early due to excess heart failure events in treatment arm.
TSUBAKI	NCT02316821	2	Diabetic Kidney Disease (DKD)	Japanese T2DM, CKD Stage 3-4	119	Change in measured GFR (inulin) at 16 weeks	Met primary endpoint; confirmed true GFR increase. Completed.
AYAME	NCT03550443	3	Diabetic Kidney Disease (DKD)	Japanese T2DM, CKD Stage 3-4	1013	Time to ≥30% eGFR decline or ESKD	Met primary endpoint but showed no benefit on hard ESKD endpoint. Development discontinued.
CARDINAL	NCT03019185	2/3	Alport Syndrome	Alport Syndrome, CKD Stage 2-4 (eGFR 30-90)	157	Change in eGFR at 48 & 100 weeks	Met primary endpoint, but benefit was not sustained off-drug. FDA/EMA rejected. Completed.
FALCON	NCT03918447	3	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	ADPKD, CKD Stage 2-4 (eGFR 30-90)	666	Change in eGFR at 108 weeks (off-treatment)	Terminated early based on disappointing AYAME results.
EAGLE	NCT03749447	3	CKD (Alport, ADPKD)	Extension study for CARDINAL/FALCON patients	270	Long-term safety	Terminated early along with FALCON.

5.1 Initial Investigations in Oncology

The clinical journey of Bardoxolone Methyl began not in nephrology, but in oncology. This was based on preclinical data demonstrating its ability to induce apoptosis and inhibit proliferation in various cancer cell lines, particularly at micromolar concentrations where it acts as a pro-oxidant.[2] A first-in-human, Phase 1 dose-escalation study was conducted in 47 patients with advanced, treatment-refractory solid tumors and lymphoid malignancies.[10] The primary objectives were to determine the safety profile, dose-limiting toxicities (DLTs), and the maximum tolerated dose (MTD).

The study established an MTD of 900 mg per day, with reversible Grade 3 elevations in liver transaminases identified as the DLT.[10] While the study showed only modest evidence of anti-tumor activity—a complete response in one patient with mantle cell lymphoma and a partial response in a patient with anaplastic thyroid carcinoma—it yielded a critical, unexpected finding.[10] A significant and consistent increase in eGFR was observed among the patients receiving Bardoxolone Methyl. This serendipitous discovery was the catalyst for a fundamental shift in the drug's development strategy.[4]

5.2 The Pivot to Nephrology: A Serendipitous Discovery

The observation of improved renal function in the Phase 1 cancer trial was a pivotal moment. It led the developers to reposition Bardoxolone Methyl from an oncology agent to a potential first-in-class therapy for chronic kidney disease.[4] The rationale was strong: CKD is characterized by chronic inflammation and oxidative stress, the very pathways targeted by Bardoxolone's dual mechanism of action. The unexpected eGFR signal provided the first human evidence that this mechanism could translate into a tangible effect on kidney function, setting the stage for a series of large-scale trials in nephrology.

5.3 Key Clinical Trials in Diabetic Kidney Disease (DKD)

5.3.1 The BEAM Study (NCT00811889): Initial Promise in Improving Renal Function

The first major foray into nephrology was the BEAM (Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes) study. This was a Phase 2b, randomized, double-blind, placebo-controlled trial that enrolled 227 patients with advanced CKD (eGFR between 20 and 45 mL/min/1.73m²) secondary to Type 2 diabetes.[21] The study was designed to assess the effect of three different doses of Bardoxolone Methyl (25, 75, and 150 mg) on renal function over one year.

The trial was a resounding success on its primary endpoint. Patients treated with Bardoxolone Methyl experienced statistically significant, dose-dependent increases in mean eGFR compared to the placebo group at 24 weeks. The between-group differences were substantial: 8.2 mL/min/1.73m² for the 25-mg group, 11.4 mL/min/1.73m² for the 75-mg group, and 10.4 mL/min/1.73m² for the 150-mg group ($p<0.001$ for all).[31] Importantly, these improvements were sustained through 52 weeks of treatment.[6] The magnitude of this effect generated considerable excitement within the nephrology community, as no existing therapy had demonstrated the ability to reverse the decline in kidney function in this manner.[36]

However, the BEAM study also revealed several concerning signals that foreshadowed future problems. A paradoxical increase in albuminuria was observed, which correlated with the increase in eGFR.[32] Other common adverse events included significant dose-dependent weight loss, a high incidence of muscle spasms (affecting 42-61% of patients on active treatment), and hypomagnesemia.[31] Furthermore, patient compliance with the assigned dose was low in the higher dose groups, presumably due to these side effects.[32]

5.3.2 The BEACON Study (NCT01351675): A Phase 3 Trial Halted by Safety Concerns

Buoyed by the positive results of BEAM, the development program rapidly advanced to a large-scale Phase 3 outcomes trial, BEACON (Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events). This multinational, randomized, double-blind, placebo-controlled study enrolled 2,185 patients with severe (Stage 4) CKD and Type 2 diabetes, a population at very high risk for progression to kidney failure and cardiovascular events.[34]

The BEACON trial ended in a catastrophic failure. In October 2012, the trial was terminated prematurely on the recommendation of its independent data monitoring committee.[35] The reason for the termination was a statistically significant and unacceptable excess of serious cardiovascular adverse events, specifically heart failure-related hospitalizations and deaths, in the group receiving Bardoxolone Methyl compared to placebo.[34]

Intensive post-hoc analyses were conducted to understand this unexpected and devastating outcome. The investigation revealed that the heart failure events were concentrated in the first four weeks of treatment and were likely caused by acute sodium and fluid retention, leading to fluid overload and precipitating heart failure in this vulnerable, high-risk patient population.[12] The risk was highest among patients with identifiable pre-existing risk factors, such as a prior history of heart failure or an elevated baseline level of B-type natriuretic peptide (BNP).[34] The underlying mechanism was hypothesized to be related to Bardoxolone's modulation of the endothelin signaling pathway, which is known to play a role in fluid balance.[40]

5.3.3 The TSUBAKI (NCT02316821) and AYAME (NCT03550443) Studies: Japanese Trials and the Hard Endpoint Dilemma

Following the BEACON failure, two key studies were conducted in Japan with modified designs aimed at mitigating the identified cardiovascular risks.

The TSUBAKI study was a Phase 2 trial in Japanese patients with Stage 3-4 CKD and Type 2 diabetes. Crucially, it excluded patients with risk factors for heart failure.[35] Its primary objective was to determine if the eGFR increase observed in previous trials represented a true change in glomerular filtration. Using inulin clearance, the gold-standard method for measuring GFR, the study confirmed that Bardoxolone Methyl produced a statistically significant increase in measured GFR compared to placebo.[13] In this carefully selected population, no heart failure events were observed, suggesting the risk could be managed through patient selection.[35]

The AYAME study was a large (N=1,013), long-term Phase 3 trial in a similar risk-mitigated Japanese population with DKD.[45] The trial was designed to assess whether Bardoxolone could slow the progression of CKD using a composite surrogate endpoint. The study successfully met its primary endpoint (time to a ≥30% decrease in eGFR from baseline or onset of ESKD) and its key secondary endpoint (time to a ≥40% decrease in eGFR from baseline or onset of ESKD).[47] Patients in the treatment group showed a statistically significant slowing of their eGFR decline.

However, despite this success on surrogate endpoints, the AYAME trial delivered a final, decisive blow to the therapeutic hypothesis for Bardoxolone in CKD. The study failed to show any statistically significant difference between the treatment and placebo groups on the most important hard clinical endpoint: the time to onset of end-stage kidney disease (ESKD).[47] This result demonstrated a critical disconnect. While the drug made the laboratory numbers (eGFR) look better over the short to medium term, it did not ultimately prevent patients from progressing to kidney failure requiring dialysis or transplantation. This failure to impact a patient-relevant hard outcome fundamentally undermined the rationale for its use in CKD and led directly to the decision by Reata Pharmaceuticals and its partner Kyowa Kirin to discontinue the entire clinical development program for Bardoxolone in this indication.[48]

5.4 Investigation in Rare Kidney Diseases

In the wake of the BEACON trial's failure, the development strategy for Bardoxolone Methyl was redirected towards rare, genetic kidney diseases where chronic inflammation is a key component of the pathophysiology and where a significant unmet medical need exists.[12]

5.4.1 The CARDINAL Trial (NCT03019185): Targeting Alport Syndrome

The CARDINAL trial was a Phase 2/3 study designed to evaluate the efficacy and safety of Bardoxolone Methyl in 157 adolescent and adult patients with Alport syndrome, a progressive genetic disorder that leads to kidney failure.[12] The trial reported that it met its primary efficacy endpoints, demonstrating a statistically significant preservation of on-treatment eGFR in the Bardoxolone group compared to the placebo group at both 48 weeks and 100 weeks.[4]

However, the trial's design and results were met with significant skepticism from regulatory authorities. A key secondary endpoint involved measuring eGFR after a 4-week washout period at the end of each year of treatment. These off-treatment measurements revealed that a substantial portion of the observed eGFR benefit disappeared upon drug discontinuation, suggesting that the effect was largely a reversible, pharmacodynamic phenomenon rather than a durable modification of the disease course.[4] The FDA conducted its own modeling and concluded that a 4-week washout was insufficient to eliminate the drug's lingering hemodynamic effects, and that a period of at least 10 weeks would be necessary, casting further doubt on the trial's primary conclusion.[13] Furthermore, despite the on-treatment eGFR differences, the number of patients who progressed to kidney failure was identical in both the treatment and placebo arms (three patients each), mirroring the hard endpoint failure seen in the AYAME trial.[52]

5.4.2 The FALCON Trial (NCT03918447): Targeting Autosomal Dominant Polycystic Kidney Disease (ADPKD)

The FALCON trial was a large, international Phase 3 study designed to assess Bardoxolone Methyl in patients with ADPKD, another progressive genetic kidney disease.[54] The trial enrolled 666 patients and was intended to run for approximately two years.

However, in May 2023, the FALCON trial was terminated prematurely.[48] This decision was not triggered by any new safety concerns emerging from within the FALCON study itself. Instead, it was a direct strategic consequence of the definitive and disappointing hard outcome results from the AYAME trial in diabetic kidney disease. The sponsor, Reata Pharmaceuticals, concluded that the failure to show a benefit on ESKD in the AYAME study meant there was no longer a viable path forward for developing Bardoxolone in any CKD indication, including ADPKD.[58]

5.5 Long-Term Extension and Other Studies (EAGLE, PHOENIX)

Several other studies were conducted to support the main development programs. The PHOENIX study (NCT03366337) was a Phase 2 open-label "basket" trial that provided the initial rationale for pursuing rare kidney diseases. It demonstrated significant increases in eGFR across four different cohorts: ADPKD, IgA nephropathy, Type 1 diabetic CKD, and focal segmental glomerulosclerosis (FSGS), suggesting a broad effect on renal function irrespective of the underlying etiology.[5]

The EAGLE study (NCT03749447) was designed as an open-label, extended access trial for patients who had completed the pivotal CARDINAL and FALCON trials.[61] Its purpose was to gather long-term safety and tolerability data in patients receiving continued treatment. Consistent with the broader program's fate, the EAGLE trial was also terminated in May 2023 following the decision to halt all CKD development.[58]

6.0 Comprehensive Safety and Tolerability Profile

The clinical development of Bardoxolone Methyl was ultimately defined by its complex and challenging safety profile. While many adverse events were manageable, the emergence of a serious cardiovascular risk in a large outcome trial proved to be an insurmountable obstacle. The systematic presentation of these risks is essential for understanding the regulatory decisions and the overall benefit-risk assessment that led to the drug's failure.

Adverse Event / Safety Finding	BEAM (Phase 2, DKD)	BEACON (Phase 3, DKD)	CARDINAL (Phase 2/3, Alport)	FALCON (Phase 3, ADPKD)	Key Observations
Heart Failure	Not identified as a significant risk	Trial-ending SAE. Significantly increased rate of hospitalization/death from HF	No significant increase in HF events (high-risk patients excluded)	No significant increase in HF events (high-risk patients excluded)	The pivotal safety concern, linked to fluid retention in high-risk Stage 4 CKD patients.
ALT/AST Elevation	Mild, dose-related increases observed	Increases observed	Increased liver enzymes in 90.9% of treated patients	ALT increased in 22.7% of patients	A consistent finding across all trials; proposed to be a pharmacodynamic effect of Nrf2 induction, not direct hepatotoxicity.
Muscle Spasms	Most frequent AE (42-61% incidence)	Reported	Commonly reported	Most common TEAE (49.0%)	A very common, generally mild-to-moderate, but persistent side effect.
Hypomagnesemia	Dose-dependent, 26% incidence	Reported	Reported	TEAE of hypomagnesemia in 5.7% of patients	A consistent laboratory abnormality of uncertain clinical significance.
Increased Albuminuria	Significant increase, correlated with eGFR rise	Increase observed	Increase in UACR observed	Increases in UACR observed	A paradoxical and concerning finding, suggesting a potentially deleterious hyperfiltration effect.
Weight Loss	Significant, dose-dependent weight loss (up to 10.1 kg)	Significant decrease in body weight (-5.7 kg vs placebo)	Average weight loss of 1kg/month	Mean decreases in body weight observed	A consistent metabolic effect, primarily due to fat loss but raised concerns about muscle wasting.

6.1 The Critical Cardiovascular Risk: Deconstructing the Heart Failure Signal from BEACON

The most significant safety issue associated with Bardoxolone Methyl was the increased risk of heart failure, which led to the premature termination of the BEACON trial.[34] In this large study of high-risk patients with Stage 4 CKD, those randomized to Bardoxolone Methyl experienced a significantly higher rate of hospitalization for heart failure or death from heart failure compared to the placebo group.[40]

Subsequent in-depth analyses pointed to acute fluid and sodium retention as the most likely underlying cause. The data showed that Bardoxolone-treated patients had a clinically meaningful reduction in 24-hour urine volume and sodium excretion within the first four weeks of treatment.[40] This fluid retention likely led to volume overload, which in turn precipitated acute heart failure events in a subset of susceptible individuals.[12] The proposed molecular mechanism for this effect involves the modulation of the endothelin signaling pathway, as the clinical phenotype observed was similar to that seen with endothelin receptor antagonists in patients with advanced CKD.[12]

The risk was not uniform across the study population. Post-hoc analyses identified two key risk factors that predicted these events: a prior history of hospitalization for heart failure and an elevated baseline B-type natriuretic peptide (BNP) level (specifically, >200 pg/mL).[34] Patients with one or both of these risk factors were significantly more likely to experience a heart failure event when treated with Bardoxolone Methyl.

6.2 Hepatic and Metabolic Effects: Understanding Aminotransferase Elevations and Weight Loss

A consistent finding across the entire clinical program was the occurrence of reversible, dose-related elevations in serum aminotransferases (ALT and AST).[10] In the CARDINAL trial, for example, increased liver enzymes were reported in over 90% of Bardoxolone-treated patients.[29] While these changes are typically a warning sign for drug-induced liver injury, further investigation suggested a different mechanism. Preclinical and clinical data supported the hypothesis that these elevations were a pharmacodynamic consequence of Nrf2-mediated transcriptional induction of the aminotransferase enzymes themselves, rather than a sign of intrinsic hepatotoxicity.[34] Despite this plausible explanation, the frequent and sometimes significant elevations in liver enzymes remained a safety concern for clinicians and regulators.

Another prominent and consistent effect was significant weight loss, which was most notable in overweight and obese patients and appeared to be dose-dependent.[33] In the BEAM study, average weight loss ranged from 7.7 kg to 10.1 kg in the active treatment groups, compared to 2.4 kg in the placebo group.[33] Evidence suggests this was primarily due to a reduction in fat mass.[33] However, this finding was complicated by the concurrent high rate of muscle spasms, which raised concerns about the possibility of muscle wasting (sarcopenia).[37] Such an effect could potentially confound the primary efficacy endpoint (eGFR), as a reduction in muscle mass would lead to lower serum creatinine production, thereby artificially inflating the calculated eGFR value without any true change in kidney function.[36]

6.3 Common Adverse Events and Laboratory Abnormalities

Beyond the major cardiovascular and hepatic signals, several other adverse events and laboratory changes were consistently reported.

• Muscle Spasms: This was one of the most frequently reported adverse events in nearly every clinical trial of Bardoxolone Methyl, affecting a large proportion of treated patients.[6] While generally reported as mild to moderate in severity, its high incidence was a significant tolerability issue.
• Hypomagnesemia: Dose-dependent decreases in serum magnesium levels were a common laboratory finding.[31] This was noted as a potential concern, as hypomagnesemia itself has been associated with a worse prognosis and faster progression of CKD.[37]
• Increased Albuminuria: The paradoxical increase in the urinary albumin-to-creatinine ratio (ACR) was a major and persistent concern throughout the development program.[12] As a key marker of glomerular injury, an increase in albuminuria is typically viewed as a negative prognostic sign. This finding strongly supported the hypothesis that the observed eGFR increase was driven by a potentially harmful increase in intraglomerular pressure and hyperfiltration, rather than a beneficial, nephroprotective effect.[29]

6.4 Evolution of Risk Mitigation Strategies in Later-Stage Trials

The catastrophic outcome of the BEACON trial prompted a significant evolution in the design of all subsequent clinical studies. The development program learned from the disaster, and later trials such as TSUBAKI, CARDINAL, AYAME, and FALCON incorporated stringent risk mitigation strategies. The most important of these was the implementation of strict exclusion criteria designed to remove patients at high risk for the previously identified heart failure events. These criteria typically excluded any patient with a prior history of heart failure, a baseline BNP level above 200 pg/mL, or clinical signs of significant fluid overload.[4] While this approach was successful in preventing a recurrence of the BEACON safety signal in later trials, it also significantly narrowed the potential patient population for whom the drug might be considered safe, and it did not address the more fundamental questions about the drug's lack of durable efficacy.

7.0 Global Regulatory Trajectory and Current Status

The clinical development of Bardoxolone Methyl culminated in a series of regulatory submissions for the treatment of chronic kidney disease (CKD) caused by Alport syndrome. Despite a focused effort on this rare disease with a high unmet need, the drug failed to gain approval from major global health authorities, leading to the eventual cessation of its development for all renal indications.

7.1 United States (FDA): The Complete Response Letter for Alport Syndrome

Following the completion of the CARDINAL trial, Reata Pharmaceuticals submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Bardoxolone Methyl for the treatment of CKD in patients with Alport syndrome.[28] The application was reviewed by the FDA's Cardiovascular and Renal Drugs Advisory Committee in December 2021. The committee's assessment was overwhelmingly negative; they voted unanimously (13-0) that the provided evidence did not demonstrate that Bardoxolone was effective in slowing the progression of CKD and that its potential benefits did not outweigh its risks.[11]

On February 25, 2022, the FDA formalized this position by issuing a Complete Response Letter (CRL) to the company, officially rejecting the NDA in its current form.[51] The FDA's rationale, as outlined in the CRL, centered on the conclusion that the submitted data failed to demonstrate a durable and clinically meaningful effect on slowing the loss of kidney function. The agency raised concerns about the trial's design, particularly the short washout period, which confounded the interpretation of the eGFR data. The FDA requested that the company provide evidence from a new, adequate, and well-controlled study showing a clinically relevant effect on either the rate of kidney function loss or a direct clinical outcome. The company was also asked to further address the drug's effect on the QT interval and to demonstrate that its clinical benefits outweigh its risks.[51]

7.2 European Union (EMA): Withdrawal of the Marketing Authorisation Application

A parallel regulatory submission was made to the European Medicines Agency (EMA) for the same indication under the proposed trade name Imbarkyd.[30] The review process by the EMA's Committee for Medicinal Products for Human Use (CHMP) also raised significant concerns.

On November 9, 2022, Reata Pharmaceuticals voluntarily withdrew its Marketing Authorisation Application.[30] The company's official letter stated that the withdrawal was based on the agency's provisional opinion that a positive benefit-risk balance could not be concluded from the submitted data.[30] The EMA's summary of its concerns at the time of withdrawal highlighted several key issues: a lack of convincing evidence for a sustained beneficial effect on kidney function, concerns about potential negative long-term effects on both kidney and heart function, and uncertainty regarding the drug's metabolic breakdown products and their potential health impact.[30]

7.3 Japan (PMDA): Discontinuation of Development for Renal Indications

In Japan, the development of Bardoxolone Methyl was led by Reata's strategic partner, Kyowa Kirin. Following the completion of the Phase 3 AYAME study, a critical decision was made. Although the study met its primary and key secondary surrogate endpoints related to eGFR decline, it crucially failed to show any benefit on the hard clinical endpoint of progression to end-stage kidney disease (ESKD).[47]

Based on this definitive result, and after discussions with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), Kyowa Kirin announced in May 2023 its decision to discontinue the entire clinical development program for Bardoxolone Methyl for diabetic kidney disease in Japan.[49] Concurrently, the company also withdrew its application for Alport Syndrome and terminated its involvement in all other ongoing CKD trials, effectively ending the drug's development for renal indications in the region.[49]

7.4 Other Jurisdictions and Orphan Drug Designations

The regulatory status in other jurisdictions, such as Australia's Therapeutic Goods Administration (TGA), is not explicitly detailed in the available documentation.[6] However, given the global discontinuation of the CKD program by the sponsors, it can be concluded that Bardoxolone is not approved for any renal indication in Australia or other major markets.

Despite these regulatory failures, it is noteworthy that Bardoxolone Methyl received Orphan Drug Designation for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease from both the FDA and the European Commission.[51] This status is granted to drugs intended for rare, life-threatening, or chronically debilitating diseases and provides regulatory and financial incentives to encourage their development. This designation underscores the significant unmet medical need in these patient populations, a need that Bardoxolone, despite its initial promise, was ultimately unable to fulfill.

8.0 Critical Analysis and Future Outlook

8.1 Synthesis of a Complex Profile: Reconciling Mechanistic Promise with Clinical Peril

Bardoxolone Methyl stands as a quintessential example of a drug with a compelling, scientifically rational, and multi-modal mechanism of action that ultimately failed due to an inseparable link between its desired pharmacodynamic effects and its unacceptable safety profile. The drug's ability to potently activate the Nrf2 pathway while simultaneously inhibiting NF-κB offered a powerful, dual-pronged approach to combatting the chronic inflammation and oxidative stress that underpin the progression of CKD. This mechanistic promise was seemingly validated by the consistent and substantial increases in eGFR observed across numerous clinical trials.

However, the very physiological changes that produced this attractive biomarker response appear to be inextricably linked to the drug's clinical peril. The hemodynamic alterations that led to an increase in glomerular filtration likely also contributed to the acute fluid and sodium retention that proved intolerable and dangerous for patients with advanced CKD and compromised cardiovascular function. The drug's profile illustrates a critical challenge in pharmacology: a potent biological effect is not synonymous with a therapeutic benefit, especially when the target pathway has pleiotropic effects that are not fully understood or controllable. The failure of Bardoxolone was not due to a lack of biological activity, but rather an inability to dissociate its potent, desired effects from its potent, dangerous ones within a clinically relevant therapeutic window.

8.2 The eGFR Conundrum: True Improvement vs. Hemodynamic Effect

The central and most debated aspect of Bardoxolone's clinical story is the nature of its effect on eGFR. The question that persisted throughout its development was whether the observed increase represented a true improvement in renal health and a slowing of disease progression, or merely a transient, pharmacodynamic, and potentially deleterious hemodynamic effect.

The evidence for a true improvement was primarily supported by the TSUBAKI study, which used the gold-standard inulin clearance method to confirm a genuine increase in GFR.[13] The persistence of a small portion of the eGFR benefit after a 4-week washout in some studies was also cited as evidence of a durable, disease-modifying effect.[12]

However, the weight of the evidence overwhelmingly points towards a predominantly hemodynamic effect. Several key observations support this conclusion:

1. Rapid Onset and Offset: The eGFR increase occurred rapidly, within the first few weeks of treatment, and a large portion of the effect dissipated just as quickly upon drug discontinuation, which is characteristic of a hemodynamic change rather than structural repair.[4]
2. Increased Albuminuria: The consistent, paradoxical increase in albuminuria that accompanied the eGFR rise is a strong indicator of increased intraglomerular pressure and hyperfiltration—a process known to accelerate long-term glomerular damage in CKD.[29]
3. Lack of Benefit on Hard Endpoints: The most definitive evidence came from the AYAME trial, which showed no difference in the rate of progression to ESKD despite a significant effect on the rate of eGFR decline.[47] This demonstrated a clear dissociation between the surrogate marker and the ultimate clinical outcome.

In synthesis, while Bardoxolone does genuinely increase the rate at which the kidneys filter blood, this effect does not appear to translate into long-term nephroprotection. Instead, it seems to represent a state of pharmacologically induced hyperfiltration that fails to alter, and may even risk accelerating, the underlying progression to kidney failure.

8.3 Lessons Learned and the Future of Nrf2 Activators in Nephrology

While Bardoxolone itself has no future in the treatment of CKD, its comprehensive and well-documented failure provides a critical roadmap and a series of invaluable lessons for the future development of drugs in this class and for nephrology in general.

The Bardoxolone program successfully validated the Nrf2 pathway as a druggable target in humans. It demonstrated that potent activation of this pathway is achievable with an oral small molecule and that this activation can produce significant physiological effects, including profound changes in renal hemodynamics.[10] The target itself remains highly attractive for treating inflammatory and fibrotic diseases. The failure of Bardoxolone was likely not a failure of the target, but a failure of the specific drug used to engage it. The molecule's potent and reactive chemical nature (a strong Michael acceptor) and its resulting off-target or pleiotropic effects, such as the apparent modulation of the endothelin pathway leading to fluid retention, were its ultimate downfall.[40]

This distinction provides a clear path forward. The next generation of Nrf2 activators must be designed with greater selectivity and a cleaner safety profile. The key challenge will be to decouple the desired anti-inflammatory and antioxidant effects of Nrf2 activation from the deleterious hemodynamic changes and fluid retention observed with Bardoxolone. This may require the development of molecules with different chemical scaffolds that are not potent Michael acceptors, that exhibit different tissue distribution profiles, or that do not interact with ancillary pathways like endothelin signaling.

Furthermore, the Bardoxolone saga has irrevocably raised the evidentiary bar for regulatory approval in CKD. Health authorities, having been confronted with a drug that improved a key surrogate marker while increasing the risk of heart failure and failing to prevent kidney failure, will be intensely skeptical of future therapies that rely solely on eGFR changes as proof of efficacy. Future development programs in this space will face intense scrutiny regarding the durability of any observed eGFR changes and will almost certainly be required to demonstrate a clear and convincing benefit on hard clinical outcomes, such as progression to ESKD or a composite of kidney failure and cardiovascular death. In essence, Bardoxolone has created a more challenging, but ultimately safer and more rigorous, development landscape for its successors.[29]

8.4 Concluding Assessment

The development of Bardoxolone Methyl for chronic kidney disease is a profound cautionary tale in modern pharmacology and clinical development. It represents a journey from immense scientific promise, through the excitement of positive surrogate endpoint data, to a catastrophic safety failure and, ultimately, a definitive lack of efficacy on hard clinical outcomes. Despite a strong and elegant scientific rationale centered on the activation of the master antioxidant regulator Nrf2, the drug's potent biological activity could not be translated into a safe and meaningful clinical benefit for patients with CKD. The inability to separate its renal hemodynamic effects from its adverse cardiovascular effects, and the ultimate demonstration that improving eGFR did not prevent kidney failure, led to its complete clinical and regulatory failure. While Bardoxolone itself will not become a therapy for kidney disease, the extensive research and hard-won lessons from its decade-long development will continue to profoundly influence and improve the design and evaluation of future therapies in nephrology for years to come.

Works cited

1. Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites - ACS Publications, accessed October 22, 2025, https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01292
2. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4211867/
3. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its | DDDT, accessed October 22, 2025, https://www.dovepress.com/bardoxolone-methyl-cddo-me-as-a-therapeutic-agent-an-update-on-its-pha-peer-reviewed-fulltext-article-DDDT
4. Bardoxolone in Alport Syndrome: The CARDINAL trial - NephJC, accessed October 22, 2025, http://www.nephjc.com/news/bardoxolone
5. Bardoxolone – Knowledge and References - Taylor & Francis, accessed October 22, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Endocrinology/Bardoxolone/
6. Bardoxolone methyl: drug development for diabetic kidney disease - PMC - PubMed Central, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7497696/
7. Definition of bardoxolone methyl - NCI Drug Dictionary, accessed October 22, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bardoxolone-methyl
8. Bardoxolone | C31H41NO4 | CID 400010 - PubChem, accessed October 22, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Bardoxolone
9. go.drugbank.com, accessed October 22, 2025, https://go.drugbank.com/drugs/DB12651#:~:text=Bardoxolone%2C%20a%20synthetic%20triterpenoid%2C%20is,levels%20of%20intrinsic%20oxidative%20stress.
10. A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas - PubMed Central, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4494099/
11. Bardoxolone methyl - Wikipedia, accessed October 22, 2025, https://en.wikipedia.org/wiki/Bardoxolone_methyl
12. Bardoxolone—the Phoenix? - PMC, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5791054/
13. Bardoxolone for CKD: The Paradox of Confusion and Dogma - PMC - NIH, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9717645/
14. bardoxolone | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 22, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=2717
15. Bardoxolone Methyl: A Comprehensive Review of Its Role as a Nrf2 Activator in Anticancer Therapeutic Applications - MDPI, accessed October 22, 2025, https://www.mdpi.com/1424-8247/18/7/966
16. Bardoxolone | CDDO | RTA 401 | CAS#218600-44-3 - MedKoo Biosciences, accessed October 22, 2025, https://www.medkoo.com/products/13569
17. Bardoxolone | 218600-44-3 - Sigma-Aldrich, accessed October 22, 2025, https://www.sigmaaldrich.com/US/en/product/ambeedinc/ambh2d6f6afc
18. CDDO (Bardoxolone, RTA 401, CAS Number: 218600-44-3) | Cayman Chemical, accessed October 22, 2025, https://www.caymanchem.com/product/81035/cddo
19. Bardoxolone | Nrf2 - TargetMol, accessed October 22, 2025, https://www.targetmol.com/compound/bardoxolone
20. EUvsVirus/MINERVA-API/ER stress.txt ... - GitLab, accessed October 22, 2025, https://git-r3lab.uni.lu/covid/models/-/blob/d385d7912eec738dcceee71d2a96cf6d4dca59a8/EUvsVirus/MINERVA-API/ER%20stress.txt
21. Bardoxolone methyl Completed Phase 2 Trials for Type 2 Diabetes Mellitus / Diabetic Nephropathy / Chronic Kidney Disease (CKD) Treatment - DrugBank, accessed October 22, 2025, https://go.drugbank.com/drugs/DB05983/clinical_trials?conditions=DBCOND0048800%2CDBCOND0028920%2CDBCOND0029752&phase=2&purpose=treatment&status=completed
22. Bardoxolone methyl Terminated Phase 2 Trials for Type 2 Diabetes Mellitus / Chronic Kidney Disease (CKD) Treatment - DrugBank, accessed October 22, 2025, https://go.drugbank.com/drugs/DB05983/clinical_trials?conditions=DBCOND0048800%2CDBCOND0029752&phase=2&purpose=treatment&status=terminated
23. Bardoxolone methyl Completed Phase 2 Trials for Chronic Kidney Disease (CKD) Treatment, accessed October 22, 2025, https://go.drugbank.com/drugs/DB05983/clinical_trials?conditions=DBCOND0048800&phase=2&purpose=treatment&status=completed
24. Bardoxolone methyl: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 22, 2025, https://go.drugbank.com/drugs/DB05983
25. bardoxolone | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 22, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=refs&ligandId=2717
26. A food effect study and dose proportionality study to assess the pharmacokinetics and safety of bardoxolone methyl in healthy volunteers - PubMed, accessed October 22, 2025, https://pubmed.ncbi.nlm.nih.gov/27128838/
27. Steady-state pharmacokinetic parameters of bardoxolone methyl - ResearchGate, accessed October 22, 2025, https://www.researchgate.net/figure/Steady-state-pharmacokinetic-parameters-of-bardoxolone-methyl_tbl1_225063734
28. Reata Pharma submits new drug application for bardoxolone to treat CKD caused by rare genetic disease - Clinical Trials Arena, accessed October 22, 2025, https://www.clinicaltrialsarena.com/analyst-comment/reata-pharma-nda-bardoxolone-ckd-genetic-disease/
29. The CARDINAL Trial of Bardoxolone Methyl in Alport Syndrome: When Marketing Interests Prevail over Patients Clinical Needs - Karger Publishers, accessed October 22, 2025, https://karger.com/nef/article/147/8/465/835893/The-CARDINAL-Trial-of-Bardoxolone-Methyl-in-Alport
30. Imbarkyd | European Medicines Agency (EMA), accessed October 22, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/imbarkyd
31. Bardoxolone methyl and kidney function in CKD with type 2 diabetes - PubMed, accessed October 22, 2025, https://pubmed.ncbi.nlm.nih.gov/21699484/
32. Bardoxolone Methyl, Chronic Kidney Disease, and... : New England Journal of Medicine - Ovid, accessed October 22, 2025, https://www.ovid.com/journals/nejm/fulltext/00006024-201111030-00034~bardoxolone-methyl-chronic-kidney-disease-and-type-2
33. Bardoxolone methyl - Alzheimer's Drug Discovery Foundation, accessed October 22, 2025, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Bardaloxone-methyl-Cognitive-Vitality-For-Researchers.pdf
34. Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD - ResearchGate, accessed October 22, 2025, https://www.researchgate.net/publication/343972864_Effects_of_Bardoxolone_Methyl_on_Hepatic_Enzymes_in_Patients_with_Type_2_Diabetes_Mellitus_and_Stage_4_CKD
35. Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study) - PMC - PubMed Central, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7271944/
36. The Extinguished BEACON of Bardoxolone: Not a Monday Morning Quarterback Story | American Journal of Nephrology | Karger Publishers, accessed October 22, 2025, https://karger.com/ajn/article/37/3/208/326058/The-Extinguished-BEACON-of-Bardoxolone-Not-a
37. The Extinguished Beacon of Bardoxolone: Not a Monday Morning Quarterback Story - PMC, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3725304/
38. Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study - PMC, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10881689/
39. Study Details | NCT00811889 | Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease | ClinicalTrials.gov, accessed October 22, 2025, https://clinicaltrials.gov/study/NCT00811889
40. Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl - Karger Publishers, accessed October 22, 2025, https://karger.com/ajn/article/39/6/499/41414/Mechanisms-Contributing-to-Adverse-Cardiovascular
41. Study Details | NCT01351675 | Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes | ClinicalTrials.gov, accessed October 22, 2025, https://www.clinicaltrials.gov/study/NCT01351675
42. Reata and Abbott Halt Phase 3 BEACON Trial For Bardoxolone Methyl Amid Serious Safety Concerns - diaTribe.org, accessed October 22, 2025, https://diatribe.org/diabetes-research/reata-and-abbott-halt-phase-3-beacon-trial-bardoxolone-methyl-amid-serious-safety
43. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl - PubMed, accessed October 22, 2025, https://pubmed.ncbi.nlm.nih.gov/24903467/
44. Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl - eScholarship.org, accessed October 22, 2025, https://escholarship.org/uc/item/75t2m9bj
45. Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study - Oxford Academic, accessed October 22, 2025, https://academic.oup.com/ndt/article/38/5/1204/6674775
46. NCT02316821 | The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes - Clinical Trials, accessed October 22, 2025, https://www.clinicaltrials.gov/study/NCT02316821
47. Bardoxolone Methyl Improves Kidney Function in Patients With Diabetic Kidney Disease, accessed October 22, 2025, https://firstwordpharma.com/story/5797847
48. Why Did the FALCON Clinical Trial End? - Polycystic kidney disease - PKD Foundation, accessed October 22, 2025, https://pkdcure.org/resources/why-did-the-falcon-clinical-trial-end/
49. Kyowa Kirin Announces Phase III Study Results of bardoxolone methyl (RTA 402) in Japan and Discontinuation of Development - FirstWord Pharma, accessed October 22, 2025, https://firstwordpharma.com/story/5737986
50. Reata, Kyowa Kirin's bardoxolone faces the music after phase 3 flop, ending 13-year saga, accessed October 22, 2025, https://www.fiercebiotech.com/biotech/reata-kyowa-kirin-partnered-med-bardoxolone-faces-music-after-ph-3-flop-ending-13-year-saga
51. FDA Rejects Reata's Bardoxolone as Treatment for Chronic Kidney Disease Caused by Alport Syndrome - Global Genes, accessed October 22, 2025, https://globalgenes.org/raredaily/fda-rejects-reatas-bardoxolone-as-treatment-for-chronic-kidney-disease-caused-by-alport-syndrome/
52. The CARDINAL Trial of Bardoxolone Methyl in Alport Syndrome ..., accessed October 22, 2025, https://pubmed.ncbi.nlm.nih.gov/36731435/
53. Study Details | NCT03019185 | A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL | ClinicalTrials.gov, accessed October 22, 2025, https://clinicaltrials.gov/study/NCT03019185
54. A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant, accessed October 22, 2025, https://www.biogentrialtransparency.com/content/dam/global-development/general/biogen-trial-link/educational/en-us/pdf/csr/NCT03918447-Synopsis.pdf
55. Study Details | NCT03918447 | A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON | ClinicalTrials.gov, accessed October 22, 2025, https://clinicaltrials.gov/study/NCT03918447
56. A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON - Clinical Trials - Study Details, accessed October 22, 2025, https://www.biogentriallink.com/en-us/home/find-a-clinical-trial/clinical-trials-study-details.html?nctId=NCT03918447
57. Kyowa Kirin initiated Phase 3 Clinical Study of Bardoxolone Methyl (RTA 402) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Japan, accessed October 22, 2025, https://www.kyowakirin.com/media_center/news_releases/2021/e20210106_01.html
58. Termination of bardoxolone methyl and chronic kidney disease research Dear PKD Foundation, This comm, accessed October 22, 2025, https://pkdcure.org/wp-content/uploads/PKD_Bardoxolone-Notification.pdf
59. 10 May 2023 Subject: Termination of bardoxolone methyl and chronic kidney disease research Dear Alport Syndrome Foundatio, accessed October 22, 2025, https://alportsyndrome.org/wp-content/uploads/2023/05/Bardoxolone-Notification-May-10-2023.pdf
60. FP117 SAFETY AND EFFICACY OF BARDOXOLONE METHYL IN PATIENTS WITH RARE CHRONIC KIDNEY DISEASES - Oxford Academic, accessed October 22, 2025, https://academic.oup.com/ndt/article/34/Supplement_1/gfz106.FP117/5514701
61. FDA Rejects Bardoxolone Methyl For Chronic Kidney Disease - HCPLive, accessed October 22, 2025, https://www.hcplive.com/view/fda-rejects-bardoxolone-methyl-chronic-kidney-disease
62. Clinical Trials – Active Studies - Alport Syndrome Foundation, accessed October 22, 2025, https://alportsyndrome.org/for-patients/clinical-trials/current-past-clinical-trials/
63. Extended Access Program for Bardoxolone Methyl in Patients with Chronic Kidney Disease (CKD) (EAGLE) - Transparency in clinical trials, accessed October 22, 2025, https://www.biogentrialtransparency.com/content/dam/global-development/general/biogen-trial-link/educational/en-us/pdf/lls/english-master/NCT03749447-LLS.pdf
64. Reata Pharmaceuticals EAGLE Statement January 21, 2022 - Alport Syndrome Foundation, accessed October 22, 2025, https://www.alportsyndrome.org/wp-content/uploads/2022/01/Reata-Pharmaceuticals-EAGLE-Statement-January-21-2022.pdf
65. An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic - Clinical Trials, accessed October 22, 2025, https://cdn.clinicaltrials.gov/large-docs/47/NCT03749447/Prot_000.pdf
66. NZ774222A - Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof - Google Patents, accessed October 22, 2025, https://patents.google.com/patent/NZ774222A/en
67. FDA Issues CRL for Bardoxolone Methyl in CKD Caused By Alport Syndrome - HCPLive, accessed October 22, 2025, https://www.hcplive.com/view/fda-issues-crl-for-bardoxolone-methyl-in-ckd-caused-by-alport-syndrome
68. March 10, 2022 Statement from Reata Pharmaceuticals to Alport Syndrome Foundation and the larger community of Alport syndrome patients and families, accessed October 22, 2025, https://www.alportsyndrome.org/wp-content/uploads/2022/03/Reata-Statement-Mar_10_22.pdf
69. re: FDA Decision on Bardoxolone Methyl - Alport Syndrome Foundation, accessed October 22, 2025, https://alportsyndrome.org/re-fda-decision-on-bardoxolone-methyl/
70. 20 December 2022 Subject: Alport syndrome EMA Application Withdrawal Dear Alport Syndrome Foundation, This letter is to in, accessed October 22, 2025, https://alportsyndrome.org/wp-content/uploads/2022/12/Reata-Pharmaceuticals-EAGLE-Statement-December-20-2022.pdf
71. TGA list SKYCLARYS on the Australian Register of Therapeutic Goods - fara Australia, accessed October 22, 2025, https://www.fara.org.au/news/tga-list-skyclarys-on-the-australian-register-of-therapeutic-goodsnbspnbsp
72. Australian Register of Therapeutic Goods (ARTG), accessed October 22, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
73. Transparency Measures Glitch Resolved: AU's TGA publishes “catch up” list for medicines accepted between February and March 2024 | Pearce IP, accessed October 22, 2025, https://www.pearceip.law/2024/03/31/transparency-measures-glitch-resolved-aus-tga-publishes-catch-up-list-for-medicines-accepted-between-february-and-march-2024/
74. Therapeutic Goods Administration (TGA) | Australian Government Department of Health, Disability and Ageing, accessed October 22, 2025, https://www.tga.gov.au/
75. Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function - PubMed, accessed October 22, 2025, https://pubmed.ncbi.nlm.nih.gov/31431054/
76. Reata Announces Orphan Drug Designation From the European Commission for Bardoxolone Methyl for the Treatment of Alport Syndrome - GlobeNewswire, accessed October 22, 2025, https://www.globenewswire.com/news-release/2018/05/31/1515191/0/en/Reata-Announces-Orphan-Drug-Designation-From-the-European-Commission-for-Bardoxolone-Methyl-for-the-Treatment-of-Alport-Syndrome.html
77. EU/3/18/2019 - orphan designation for treatment of Alport syndrome, accessed October 22, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2019
78. Search Orphan Drug Designations and Approvals - FDA, accessed October 22, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=687219